Effect of Long-term Carbamazepine Therapy on Bone Health

  title={Effect of Long-term Carbamazepine Therapy on Bone Health},
  author={Enra Mehmedika Suljic and Admir Mehi{\vc}evi{\'c} and Nevena Mahmutbegovi{\'c}},
  journal={Medical Archives},
  pages={262 - 266}
Introduction: Recent research reported that prolonged use of AET is associated with changes in bone metabolism, with consequent reduction in bone mineral density (BMD) and increased risk of fractures. Objectives: Therefore, the aim of our study was to investigate the effects of carbamazepine on serum levels of 25 -hydroxyvitamin D and on biomarker of bone formation and resorption (serum levels of osteocalcin). Material and methods: We measured serum levels of 25-OHD and osteocalcin (OCLN) in… 

Tables from this paper

The Effect of Pregabalin on Bone Metabolism.

  • Burcak AkinB. KelleE. Kozanoğlu
  • Medicine, Biology
    Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry
  • 2021

Effect of carbamazepine on the bone health of people with epilepsy: a systematic review and meta-analysis

Evidence is provided that CBZ treatment has a negative effect on bone health in PWE with skeletal diseases or osteoporosis, and clinical implications are that long-termCBZ treatment may not be a good choice for people with epilepsy with skeletal illnesses.


There was a significant osteopenia prevalence difference between male and female epilepsy patients taking combination of carbamazepine and valproic acid and moderate and strong relationship were found between oste Openia and clinical characteristics epilepsy.

Drugs Causing Bone Loss.

  • P. Vestergaard
  • Biology, Medicine
    Handbook of experimental pharmacology
  • 2019
This paper performs a systematic review of drugs inducing bone loss or associated with fracture risk and is organized by the Anatomical Therapeutic Chemical (ATC) classification.

Prevalence of anticonvulsant-induced vitamin D deficiency

The results of the review showed high relevance of the discussed interdisciplinary problem and need to introduce laboratory screening of vitamin D deficiency among pediatric and adult patients with epilepsy.

Changes in bone metabolism during cerebral palsy

Indicators of bone tissue resorption (β-CrossLaps) in patients with cerebral palsy increased significantly more than in patients of the comparison group, which indicates a pronounced loss of bone mass in severe impairment of motor functions.

Effects of Neurological Disorders on Bone Health

Gaining a better understanding of brain-bone interactions, particularly in patients with underlying neurological disorders, may lead to development of novel therapies and discovery of shared risk factors, and highlight the need for broad, whole-health clinical approaches toward treatment.

Role of oxidative metabolism in osseointegration during spinal fusion

It is concluded that higher oxidative metabolism in BMSCs correlates with better spinal fusion outcomes in both human patients and in a mouse model, and suggests that promoting antioxidant metabolism in osteogenic cells could improve spinal fusion outcome for patients.



Effects of antiepileptic drug therapy on vitamin D status and biochemical markers of bone turnover in children with epilepsy

The results indicate that the prevalence of vitamin D deficiency in epilepsy patients under AED treatment is high, especially under polytherapy, and alteration markers of bone formation and resorption suggests an accelerated skeletal turnover.

Antiepileptics and bone health

For patients with long-term AED exposure, BMD measurement is recommended as part of osteoporosis investigation and drug therapy is reserved for the treatment of patients who have a high fracture risk; there are no specific intervention studies available in patients with epilepsy.

Effect of antiepileptic drugs on bone density in ambulatory patients

Epilepsy and its therapy, including the newer drugs, are risk factors for low bone density, irrespective of vitamin D levels, as well as single vs multiple therapy on bone density.

Long-term anticonvulsant therapy leads to low bone mineral density--evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells.

Clinical and experimental data indicate that long-term treatment with anticonvulsant drugs leads to a lower bone mineral density (BMD), and the experimentally observed decrease in bone cell proliferation might be clinically associated with impaired new bone formation.

Effects of carbamazepine on serum parathormone, 25- hydroxyvitamin D, bone specific alkaline phosphatase, C-telopeptide, and osteocalcin levels in healthy rats.

The main outcome of this prospective study in healthy rats showed no change in biochemical parameters of bone turnover during treatment with carbamazepine, and serum levels of 25-hydroxyvitamin D and parathormone and osteocalcin were found to be significantly higher in control group compared to isotonic saline solution group and carbsepine group.

Pathophysiology of bone loss in patients receiving anticonvulsant therapy

Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy

The results demonstrate that phenytoin is associated with changes in bone metabolism and increased bone turnover, and the lower calcium concentrations in subjects taking carbamazepine or valproate compared with those taking other antiepileptic drugs suggest that these antie P450 enzyme inducers may have long‐term effects.

Antiepileptic Treatment Is Associated with Bone Loss: Difference in Drug Type and Region of Interest

AED therapy, especially in patients on new-generation medication, is associated with low bone density, and is hoped that the presented data stressing several clinical and diagnostic points will stimulate a high index of suspicion to facilitate early diagnosis and preventive care.

The effects of antiepileptic drugs on the relationships between leptin levels and bone turnover in prepubertal children with epilepsy

It is demonstrated that the markers of bone formation and resorption increased with CBZ and decreased with VPA treatment without affecting BMD and vitamin D levels in prepubertal epileptic children.